A Pragmatic Tele-Nursing Program Improves Satisfaction of Patients with Pulmonary Fibrosis and Their Caregivers—A Pilot Study
Abstract
1. Introduction
2. Methods
2.1. Nursing Standard Care
2.2. Study Intervention
2.3. Statistical Analysis
3. Results
4. Discussion
4.1. Strengths and Limitations
4.2. Practical Implications
4.3. Study Implications and Future Research
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
IPF | idiopathic pulmonary fibrosis |
ILD | interstitial lung disease |
PPF | progressive pulmonary fibrosis |
FVC | forced vital capacity |
DLCO | diffusing capacity of the lung for carbon monoxide |
BMI | body mass index |
6MWD | six-minute walk distance |
mMRC | modified Medical Research Council |
PREMs | patient-reported experience measures |
PROMs | patient-reported outcome measures |
K-BILD | King’s Brief Interstitial Lung Disease questionnaire |
L-PF | Living with Pulmonary Fibrosis questionnaire |
HRQOL | health-related quality of life |
IQR | interquartile range |
SD | standard deviation |
CEIm | research ethics committee |
References
- Raghu, G.; Remy-Jardin, M.; Myers, J.L.; Richeldi, L.; Ryerson, C.J.; Lederer, D.J.; Behr, J.; Cottin, V.; Danoff, S.K.; Morell, F.; et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2018, 198, e44–e68. [Google Scholar] [CrossRef]
- Raghu, G.; Collard, H.R.; Egan, J.J.; Martinez, F.J.; Behr, J.; Brown, K.K.; Colby, T.V.; Cordier, J.-F.; Flaherty, K.R.; Lasky, J.A.; et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011, 183, 788–824. [Google Scholar] [CrossRef] [PubMed]
- Raghu, G.; Remy-Jardin, M.; Richeldi, L.; Thomson, C.C.; Inoue, Y.; Johkoh, T.; Kreuter, M.; Lynch, D.A.; Maher, T.M.; Martinez, F.J.; et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2022, 205, e18–e47. [Google Scholar] [CrossRef] [PubMed]
- Wijsenbeek, M.; Cottin, V. Spectrum of Fibrotic Lung Diseases. N. Engl. J. Med. 2020, 383, 958–968. [Google Scholar] [CrossRef] [PubMed]
- Flaherty, K.R.; Wells, A.U.; Cottin, V.; Devaraj, A.; Walsh, S.L.; Inoue, Y.; Richeldi, L.; Kolb, M.; Tetzlaff, K.; Stowasser, S.; et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N. Engl. J. Med. 2019, 381, 1718–1727. [Google Scholar] [CrossRef]
- Crestani, B.; Huggins, J.T.; Kaye, M.; Costabel, U.; Glaspole, I.; Ogura, T.; Song, J.W.; Stansen, W.; Quaresma, M.; Stowasser, S.; et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: Results from the open-label extension study, INPULSIS-ON. Lancet Respir. Med. 2019, 7, 60–68. [Google Scholar] [CrossRef]
- Richeldi, L.; Du Bois, R.M.; Raghu, G.; Azuma, A.; Brown, K.K.; Costabel, U.; Cottin, V.; Flaherty, K.R.; Hansell, D.M.; Inoue, Y.; et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 2014, 370, 2071–2082. [Google Scholar] [CrossRef]
- Noble, P.W.; Albera, C.; Bradford, W.Z.; Costabel, U.; du Bois, R.M.; Fagan, E.A.; Fishman, R.S.; Glaspole, I.; Glassberg, M.K.; Lancaster, L.; et al. Pirfenidone for idiopathic pulmonary fibrosis: Analysis of pooled data from three multinational phase 3 trials. Eur. Respir. J. 2015, 47, 243–253. [Google Scholar] [CrossRef]
- Platenburg, M.G.J.P.; van Moorsel, C.H.M.; Wiertz, I.A.; van der Vis, J.J.; Vorselaars, A.D.M.; Veltkamp, M.; Grutters, J.C. Improved Survival of IPF patients Treated With Antifibrotic Drugs Compared With Untreated Patients. Lung 2023, 201, 335–343. [Google Scholar] [CrossRef]
- Chong, W.H.; Agrawal, D.; Tan, Z.Y.; Venkateswaran, S.; Tan, A.Y.Y.; Tan, C.Y.; Ling, N.C.A.; Tay, N.S.W.T. A systematic review and meta-analysis of the clinical benefits and adverse reactions of anti-fibrotics in non-IPF progressive fibrosing ILD. Heart Lung 2024, 68, 242–253. [Google Scholar] [CrossRef]
- Russell, A.M.; Olive, S.; Lines, S.; Murphy, A.; Hocking, J.; Newell, K.; Morris, H.; Harris, E.; Dixon, C.; Agnew, S.; et al. Contemporary challenges for specialist nursing in interstitial lung disease. Breathe 2018, 14, 36. [Google Scholar] [CrossRef] [PubMed]
- Oliveira, A.; Fabbri, G.; Gille, T.; Bargagli, E.; Duchemann, B.; Evans, R.; Pinnock, H.; Holland, A.E.; Renzoni, E.; Ekström, M.; et al. Holistic management of patients with progressive pulmonary fibrosis. Breathe 2023, 19, 230101. [Google Scholar] [CrossRef] [PubMed]
- Sampson, C.; Gill, B.H.; Harrison, N.K.; Nelson, A.; Byrne, A. The care needs of patients with idiopathic pulmonary fibrosis and their carers (CaNoPy): Results of a qualitative study. BMC Pulm. Med. 2015, 15, 155. [Google Scholar] [CrossRef] [PubMed]
- Hofman, D.E.; Magrì, T.; Moor, C.C.; Richeldi, L.; Wijsenbeek, M.S.; Waseda, Y. Patient-centered care in pulmonary fibrosis: Access, anticipate, and act. Respir. Res. 2024, 25, 395. [Google Scholar] [CrossRef]
- Althobiani, M.; Alqahtani, J.S.; Hurst, J.R.; Russell, A.M.; Porter, J. Telehealth for patients with interstitial lung diseases (ILD): Results of an international survey of clinicians. BMJ Open Respir. Res. 2021, 8, e001088. [Google Scholar] [CrossRef]
- Scott Kruse, C.; Karem, P.; Shifflett, K.; Vegi, L.; Ravi, K.; Brooks, M. Evaluating barriers to adopting telemedicine worldwide: A systematic review. J. Telemed. Telecare 2018, 24, 4–12. [Google Scholar] [CrossRef]
- Kao, C.K.; Liebovitz, D.M. Consumer Mobile Health Apps: Current State, Barriers, and Future Directions. PM&R 2017, 9, S106–S115. [Google Scholar] [CrossRef]
- Moor, C.C.; Mostard, R.L.M.; Grutters, J.C.; Bresser, P.; Aerts, J.G.J.V.; Chavannes, N.H.; Wijsenbeek, M.S. Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. Am. J. Respir. Crit. Care Med. 2020, 202, 393–401. [Google Scholar] [CrossRef]
- Moor, C.C.; Van Leuven, S.I.; Wijsenbeek, M.S.; Vonk, M.C. Feasibility of online home spirometry in systemic sclerosis–associated interstitial lung disease: A pilot study. Rheumatology 2020, 60, 2467. [Google Scholar] [CrossRef]
- Ilić, M.; Javorac, J.; Milenković, A.; Živanović, D.; Miljković, D.; Lečić, S.K.; Savić, N.; Vereš, K.T.; Kovačević, D.; Vujičić, E.; et al. Home-Based Spirometry in Patients with Interstitial Lung Diseases: A Real-Life Pilot “FACT” Study from Serbia. J. Pers. Med. 2023, 13, 793. [Google Scholar] [CrossRef]
- Greenhalgh, T.; Vijayaraghavan, S.; Wherton, J.; Shaw, S.; Byrne, E.; Campbell-Richards, D.; Bhattacharya, S.; Hanson, P.; Ramoutar, S.; Gutteridge, C.; et al. Virtual online consultations: Advantages and limitations (VOCAL) study. BMJ Open 2016, 6, e009388. [Google Scholar] [CrossRef]
- Kalluri, M.; Luppi, F.; Ferrara, G. What Patients With Idiopathic Pulmonary Fibrosis and Caregivers Want: Filling the Gaps With Patient Reported Outcomes and Experience Measures. Am. J. Med. 2020, 133, 281–289. [Google Scholar] [CrossRef]
- Khor, Y.H.; Poberezhets, V.; Buhr, R.G.; Chalmers, J.D.; Choi, H.; Fan, V.S.; George, M.; Holland, A.E.; Pinnock, H.; Ryerson, C.J.; et al. Assessment of Home-based Monitoring in Adults with Chronic Lung Disease: An Official American Thoracic Society Research Statement. Am. J. Respir. Crit. Care Med. 2024, 211, 174. [Google Scholar] [CrossRef] [PubMed]
- Mann, J.; Barnes, H.; Lew, J.; Khor, Y.H.; Goh, N.; Holland, A.E. Patient-reported outcome measures for cough used in interstitial lung disease: A systematic review. Eur. Respir. Rev. 2025, 34, 240206. [Google Scholar] [PubMed]
- Wells, M.; Harding, S.; Dixon, G.; Buckley, K.; Russell, A.M.; Barratt, S.L. Patient and caregiver shared experiences of pulmonary fibrosis (PF): A systematic literature review. Respir. Med. 2024, 227, 107659. [Google Scholar] [CrossRef] [PubMed]
- Calypso, A.; Danoff, S.K.; Gersten, R.A. Addressing advance care planning for idiopathic pulmonary fibrosis: A call to action. Expert Rev. Respir. Med. 2025, 1–9. [Google Scholar] [CrossRef]
- Wijsenbeek, M.S.; Moor, C.C.; Johannson, K.A.; Jackson, P.D.; Khor, Y.H.; Kondoh, Y.; Rajan, S.K.; Tabaj, G.C.; Varela, B.E.; van der Wal, P.; et al. Home monitoring in interstitial lung diseases. Lancet Respir. Med. 2023, 11, 97–110. [Google Scholar] [CrossRef]
- Althobiani, M.A.; Evans, R.A.; Alqahtani, J.S.; Aldhahir, A.M.; Russell, A.-M.; Hurst, J.R.; Porter, J.C. Home monitoring of physiology and symptoms to detect interstitial lung disease exacerbations and progression: A systematic review. ERJ Open Res. 2021, 7, 00441-2021. [Google Scholar] [CrossRef]
- Saigí-Rubió, F.; Nascimento, I.J.B.D.; Robles, N.; Ivanovska, K.; Katz, C.; Azzopardi-Muscat, N.; Ortiz, D.N. The Current Status of Telemedicine Technology Use Across the World Health Organization European Region: An Overview of Systematic Reviews. J. Med. Internet Res. 2022, 24, e40877. [Google Scholar] [CrossRef]
- Boente, R.D.; Schacht, S.; Borton, R.; Vincent, J.; Golzarri-Arroyo, L.; Rattray, N. Assessing the acceptability and feasibility of remote spirometric monitoring for rural patients with interstitial lung disease: A multimethod approach. Respir. Res. 2024, 25, 92. [Google Scholar] [CrossRef]
- De Albornoz, S.C.; Sia, K.L.; Harris, A. The effectiveness of teleconsultations in primary care: Systematic review. Fam. Pract. 2022, 39, 168–182. [Google Scholar] [CrossRef]
Characteristics | N = 47 | |
---|---|---|
Male, n (%) | 33 (70%) | |
Age, mean (SD) | 72.9 (8.2) | |
Diagnosis, n (%) | IPF | 18 (38%) |
Hypersensitivity pneumonitis | 15 (32%) | |
Connective tissue disease-associated | 5 (11%) | |
Unclassifiable | 3 (6%) | |
Other types | 6 (13%) | |
Severe pulmonary fibrosis, n (%) | FVC < 50% and/or DLCO < 30% | 11 (23%) |
Cough, n (%) | 15 (32%) | |
Dyspnoea mMRC, n (%) | Grade 0 | 9 (19%) |
Grade 1 | 20 (43%) | |
Grade 2 | 12 (26%) | |
Grade 3 | 6 (13%) | |
Antifibrotic side effects, n (%) | 19 (40%) | |
BMI, mean (SD) | 27.9 (3.6) | |
FVC (L), mean (SD) | 3.2 (0.7) | |
FVC (%), mean (SD) | 78.7 (18.9) | |
DLCO (%), mean (SD) | 50.5 (15.1) | |
6MWT (m), mean (SD) | 355.7 (111.1) |
PATIENT | N | ||||
---|---|---|---|---|---|
PREMs | Basal | After | p-Value | ||
(I feel) | Mean (SD) | Mean (SD) | |||
1 | Having a nurse is essential for my care | 9.1 (1.3) | 9.8 (0.7) | 0.004 | 43 |
2 | Access to the nurse is easy | 6.7 (2.6) | 9.4 (1.0) | 0.000 | 43 |
3 | Access to the nurse has been available when I needed it | 6.7 (2.6) | 9.6 (0.9) | 0.000 | 43 |
4 | All necessary information on symptom management has been provided | 7.2 (2.3) | 9.4 (1.0) | 0.000 | 43 |
5 | Security in all forms of contact with the nurse | 7 (2.4) | 9.3 (1.4) | 0.000 | 43 |
6 | The healthcare service is well organized | 6.9 (2.7) | 9.2 (1.2) | 0.000 | 43 |
7 | Concern for my well-being and issues | 7.7 (2.6) | 9.6 (0.8) | 0.000 | 43 |
8 | Resolution of my lung disease | 7 (2.6) | 9.3 (1.2) | 0.000 | 43 |
9 | Good management of symptoms | 7.1 (2.5) | 8.8 (1.3) | 0.000 | 43 |
10 | Comforted by the attention received | 7.2 (2.7) | 9.4 (1.1) | 0.000 | 43 |
11 | Self-control over the disease and its treatment | 6.9 (2.8) | 8.7 (1.6) | 0.000 | 43 |
12 | Rate satisfaction with the care received | 7.4 (2.7) | 9.5 (1.0) | 0.000 | 43 |
13 | Rate the nurse’s impact on health | 8 (1.8) | 9 (1.6) | 0.007 | 43 |
14 | Rate the importance of remote access to nurse | 8.4 (2.0) | 9.7 (0.8) | 0.000 | 43 |
PROMs | |||||
K-BILD | 53.9 (9.8) | 53.4 (15.0) | 0.797 | 37 | |
L-PF Impact | 48.7 (24.6) | 45.3 (22.9) | 0.219 | 41 | |
L-PF Symptoms | 30.9 (21.1) | 30.6 (22.1) | 0.912 | 41 | |
CAREGIVER | |||||
1 | Having a nurse is essential for his/her care | 8.9 (1.9) | 9.5 (1.1) | 0.096 | 34 |
2 | Access to the nurse is easy | 6.8 (2.9) | 9.1 (1.3) | 0.000 | 34 |
3 | Access to the nurse has been available when he/she needed it | 6.9 (2.8) | 9.3 (1.3) | 0.000 | 34 |
4 | All necessary information on symptom management has been provided | 7.4 (2.8) | 9.3 (1.2) | 0.001 | 34 |
5 | Security in all forms of contact with the nurse | 6.7 (3.0) | 9.2 (1.4) | 0.000 | 34 |
6 | The healthcare service is well organized | 7 (2.9) | 9.4 (1.0) | 0.000 | 34 |
7 | Concern for his/her well-being and issues | 7.5 (2.9) | 9.5 (0.9) | 0.000 | 34 |
8 | Resolution of his/her lung disease | 7.1 (2.7) | 9.3 (1.2) | 0.000 | 34 |
9 | Good management of his/her symptoms | 7.1 (2.6) | 8.7 (1.3) | 0.000 | 34 |
10 | Comforted by the attention received | 7.2 (2.8) | 9.5 (1.0) | 0.000 | 34 |
11 | Self-control over the disease and its treatment | 6.5 (2.8) | 8.6 (1.5) | 0.000 | 34 |
12 | Rate satisfaction with the care received | 7.4 (2.7) | 9.6 (0.8) | 0.000 | 34 |
13 | Rate the nurse’s impact on health | 8 (2.2) | 9.3 (1.3) | 0.003 | 34 |
14 | Rate the importance of remote access to nurse | 9.0 (1.9) | 9.6 (0.9) | 0.084 | 34 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Baiges, M.; Iglesias, D.; Persentili, S.; Jiménez, M.; Ortega, P.; Bordas-Martinez, J. A Pragmatic Tele-Nursing Program Improves Satisfaction of Patients with Pulmonary Fibrosis and Their Caregivers—A Pilot Study. Medicina 2025, 61, 1385. https://doi.org/10.3390/medicina61081385
Baiges M, Iglesias D, Persentili S, Jiménez M, Ortega P, Bordas-Martinez J. A Pragmatic Tele-Nursing Program Improves Satisfaction of Patients with Pulmonary Fibrosis and Their Caregivers—A Pilot Study. Medicina. 2025; 61(8):1385. https://doi.org/10.3390/medicina61081385
Chicago/Turabian StyleBaiges, Mireia, David Iglesias, Sara Persentili, Marta Jiménez, Pilar Ortega, and Jaume Bordas-Martinez. 2025. "A Pragmatic Tele-Nursing Program Improves Satisfaction of Patients with Pulmonary Fibrosis and Their Caregivers—A Pilot Study" Medicina 61, no. 8: 1385. https://doi.org/10.3390/medicina61081385
APA StyleBaiges, M., Iglesias, D., Persentili, S., Jiménez, M., Ortega, P., & Bordas-Martinez, J. (2025). A Pragmatic Tele-Nursing Program Improves Satisfaction of Patients with Pulmonary Fibrosis and Their Caregivers—A Pilot Study. Medicina, 61(8), 1385. https://doi.org/10.3390/medicina61081385